Search for: rheumatoid arthritis methotrexate autoimmune disease biomarker gene expression GWAS HLA genes non-HLA genes
| ID | PMID | Title | PublicationDate | abstract |
|---|---|---|---|---|
| 3125798 | Measurement of 'free' gold in patients receiving disodium aurothiomalate and the associati | 1988 Jan | Serum from patients with rheumatoid arthritis (RA) receiving disodium aurothiomalate was analysed for total gold by atomic absorption spectrometry and for unbound (free) gold by the same method after ultrafiltration by an inert membrane. It was shown that it is possible to obtain reliable free gold concentrations by this method. Good correlations were shown between total and 'free' gold and between total and protein bound gold (PBG) for 54 patients with RA who were stabilised on gold therapy. Significant correlation was also shown between the same parameters for a second group of 15 patients starting gold therapy who were bled at weekly intervals for nine weeks immediately before medication. A single correlation with regression for all patients studied again showed good correlation between total and free gold and between total and PBG. Of the 189 paired values plotted, 182 fell within 2SD of the regression lines for the two plots. Of the seven patients with results outside 2SD of the regression line, six presented with side effects during the study. | |
| 2928510 | [Enthesopathic reactions of the wrist in psoriatic arthritis, chronic polyarthritis and di | 1989 Feb | Twenty-six sites of muscle and ligament attachment around the wrist were evaluated for enthesopathic proliferative bone changes in psoriatic arthritis (PA), rheumatoid arthritis (RA), and diffuse idiopathic skeletal hyperostosis (DISH). Proliferations were found to be most frequent, most irregular, and largest in PA, followed in declining order by RA and DISH. In PA only, the bony proliferations and the underlying bone often had the appearance of mineralized woven bone, though smooth proliferations with a regular bone structure do occur in PA as well as in RA. The entheses of the trapezium, scaphoid and the radial styloid process are most frequently affected, followed by the bases of the first and fifth metacarpals and the pisiform. It is exceptional for huge bony proliferations to be observed at the entheses in DISH. | |
| 3352898 | Use of Halifax interlaminar clamps for posterior C1-C2 arthrodesis. | 1988 Feb | Eight patients with atlantoaxial instability secondary to trauma or rheumatoid arthritis were treated with posterior C1-C2 arthrodesis using the Halifax interlaminar clamp and autogenous bone graft or methylmethacrylate. Thus far, with an average follow-up of 6 months, satisfactory stability has been achieved with no instrument failure. | |
| 2229835 | Arthritis and mast cell activation. | 1990 Oct | The significance of the mast cell in the pathogenesis of rheumatic diseases continues to receive attention. Increased numbers of mast cells are found in the synovial tissue and fluid of patients with inflammatory arthritides, and these mast cells can be activated by many of the substances found in inflammatory synovial fluid. This activation results in the release of mediators that are capable of amplifying the inflammatory process within the joint space. Recent research has shown that mast cells also produce a variety of cytokines and hematopoietic growth factors that may have paracrine and autocrine functions that are important to the development of the inflammatory cell infiltrate. Increased numbers of mast cells are also found in many fibrotic conditions, including scleroderma. These mast cells, directly or through mediator generation, affect the function of endothelial cells, fibroblasts, and growth factors important to the proliferation and function of these cells. A clearer understanding of mast cell involvement in the inflammatory arthritides and fibrotic processes should lead to new therapeutic strategies. | |
| 2224400 | Impaired iron uptake and transferrin binding by erythroblasts in the anaemia of rheumatoid | 1990 Oct | Serum and bone marrow from 18 patients with rheumatoid arthritis (RA) and five healthy controls were studied in order to establish a possible role of impaired iron uptake and transferrin binding by erythroblasts in the pathophysiology of anaemia of chronic disease (ACD) in RA. Iron incorporation into erythroblasts was reduced in patients with ACD using a method based on incubation of erythroblasts with radiolabelled 59Fe-125I-transferrin. It correlated negatively with C-reactive protein (CRP). In iron deficient RA patients it tended to be reduced as well. These patients had the same level of RA disease activity as in ACD. Transferrin binding by erythroblasts was significantly impaired in ACD compared to controls, although it tended to be reduced in all RA groups. These findings suggest that impaired iron uptake by erythroblasts, probably due to decreased transferrin binding to erythroblasts, might be a pathophysiological factor in ACD in RA. | |
| 3789829 | Osteoporosis in rheumatoid arthritis: safety of low dose corticosteroids. | 1986 Nov | Fear of inducing generalised osteoporosis is one reason why corticosteroids are withheld in patients with rheumatoid arthritis (RA). No studies, however, have directly measured bone density in such patients at clinically relevant sites. To assess this risk we measured bone mineral density in the lumbar spine and femoral neck by dual photon absorptiometry in 84 patients with RA, 44 of whom had been treated with low dose prednis(ol)one (mean dose +/- SE 8.0 +/- 0.5 mg/day; mean duration of treatment 89.6 +/- 12.0 months). There were significant reductions in bone mineral density in patients treated with corticosteroids (lumbar 9.6%, p less than 0.001; femoral 12.2%, p less than 0.001) and in those who had not received corticosteroids (lumbar 6.9%, p less than 0.01; femoral 8.9%, p less than 0.001), but the differences between the two groups were not significant. We conclude on the basis of these studies that low dose oral corticosteroids do not increase the risk of generalised osteoporosis in patients with rheumatoid arthritis. | |
| 3763218 | [Cervical spine in polyarthritis. Radiology, indications for surgery and results]. | 1986 Aug | The rheumatoid changes in the spine that are of clinical importance are in the cervical part. They may cause dislocations in the cranio-vertebral region and - more uncommon - in lower levels. Most common is the horizontal dislocation between CI and CII, caused by destruction of the odontoid process and the area around it. This type can progress and give rise to the vertical dislocation caused by bone destruction in the joints between the occiput, CI and CII. The diagnosis is partly clinical and partially made by X-ray films. New radiological methods and new ways of using the old ones are discussed. Subaxial dislocations are not rare. Indications for surgery (fusion and possibly decompression) depend upon the progress of clinical symptoms and radiological findings, as do the surgical methods. The use of bone cement is increasing. Most authors advocate earlier surgical treatment. Subaxial fusion is difficult because of the poor condition of the bone. | |
| 2765396 | The production of arthritis in the guinea-pig by intra-articular reaction between lymphoki | 1989 Aug | A single intra-articular injection of lymphokine into the guinea-pig knee joint resulted in a sequence of changes in joint architecture whose histopathological features resembled that of an acute inflammatory reaction progressing to a chronic state. At 24 h there was a mild hyperplasia and hypertrophy of the synovium with intense polymorphonuclear leucocyte infiltration. At 72 h, the synovium was heavily infiltrated with diffuse and focal aggregations of mononuclear cells; erosion of cartilage and bone by synovial pannus was accompanied by a subsynovial fibrosis. By 1 week, leucocytic infiltration of the synovium had decreased markedly although the erosion and fibrosis persisted. However, when lymphokine was injected together with oil-elicited peritoneal exudate cells a more intense arthritis ensued: at 72 h synovial pannus was prominently eroding bone and this was accompanied by the appearance of multinucleate cells resembling osteoclasts in the zone of erosion. These features were shown to resemble closely the histopathology of experimental allergic arthritis in the guinea-pig, in contrast to the lesser severity of synovitis resulting from the adoptive cellular transfer of delayed hypersensitivity into the joint. The results indicate that lymphokines may play a role in the induction of experimental allergic arthritis by recruiting and activating cells involved in chronic inflammation. | |
| 2805426 | Anti-endothelial cell antibodies in patients with rheumatoid arthritis complicated by vasc | 1989 Oct | IgG antibodies reactive with human umbilical vein endothelial cells were found in 19 out of 28 patients with rheumatoid vasculitis (RV), in four out of 24 patients with rheumatoid arthritis (RA), in seven out of 10 patients with systemic lupus erythematosus (SLE), but not in healthy donors. In four patients with RV who were followed longitudinally, regression of vasculitic episodes coincided with decreasing titres of anti-endothelial antibodies (AEA). Binding activity to endothelial cells was observed in intact IgG and F(ab')2 fragments of IgG. AEA activity was unrelated to antibodies against nuclear, blood group or major histocompatibility complex antigens and did not involve immune complexes. AEA activity was not specific for endothelial cells since the AEA-positive sera and the IgG fractions prepared from these sera also reacted with fibroblasts. Adsorption of positive sera and corresponding IgG fractions with endothelial cells decreased the IgG binding reactivity on both fibroblasts and endothelial cells. These findings show that RV patients have IgG-AEA, and suggest that these antibodies may play a role in the pathogenesis of the disease. | |
| 2086008 | [Detection of serum anti-salivary duct antibody and its clinical significance]. | 1990 Nov | The authors developed an indirect immunofluorescence technique for the detection of Anti-salivary duct antibody (ASDA) and screened 34 patients with rheumatoid arthritis, 15 patients with Sjögren's syndrome-rheumatoid arthritis and 15 patients with primary Sjögren's syndrome, 63 cases with other connective tissue diseases, 9 cases with other diseases and 40 normal controls. The incidence of ASDA in patients with Sjögren's syndrome rheumatoid arthritis (66.67%) or rheumatoid arthritis (32.35%) was significantly higher than that in normal controls (P less than 0.001). In patients with primary Sjögren's syndrome and other CTDs, non-CTDs, no ASDA was found. However, in patients with Sjögren's syndrome-rheumatoid arthritis or rheumatoid arthritis alone, ASDA was not correlated with age, sex, disease duration or serological findings. The result suggests that the detection of serum ASDA might be useful in the differentiation of Sjögren's syndrome with rheumatoid arthritis from primary Sjögren's syndrome with arthralgia and/or arthritis. | |
| 3494120 | Increased expression of Epstein-Barr virus receptor on lymphoblastoid cell lines from subs | 1986 Dec | We studied the expression of Epstein-Barr virus receptor (EBVR/CR2) on lymphoblastoid cell (LCL) lines established from 23 patients with rheumatoid arthritis and the T cell suppression of IgM secretion by EBV activated B cells. Ten patients had normal T cell suppression of IgM secretion, whereas 13 patients had defective suppressor T cell function. EBVR expression on LCL was assessed using a rabbit anti-gp 140 IgG; Raji cells, used as reference cell line expressed 50,000 EBVR, a 140 k glycoprotein (gp 140). Patients with defective T cell suppression of IgM secretion by EBV activated B cells had a significantly higher EBVR expression on LCL than patients with normal T cell suppression (mean +/- SD; 50.8 +/- 23.8 vs 29.5 +/- 13.2, respectively; p less than 0.05). These data suggest a relationship between the T cell suppression defect and an increased EBVR expression on LCL from patients with RA. | |
| 3037823 | [Circadian rhythm of cortisol and corticotropin (ACTH) in patients with rheumatoid arthrit | 1987 Mar | In patients with rheumatoid arthritis, corticosteroids are usually given as a single morning dose to minimize adrenal suppression, because of the well-known circadian rhythm of the secretion of cortisol and corticotropin. However, it has not been so far examined whether there really is a normal secretion pattern of those hormones in all patients with rheumatoid arthritis, as there is in healthy subjects. We therefore studied twelve patients with rheumatoid arthritis who had never been treated before with corticosteroids and disease-modifying drugs such as gold, D-penicillamine or immunosuppressive drugs. The study was designed to examine adrenal secretory activity by measuring the cortisol and corticotropin levels at 2 h intervals throughout a 24 h cycle. The circadian secretion patterns of cortisol and corticotropin were disturbed in most patients. High inflammatory activity of the disease was accompanied by a severe disturbance of the circadian rhythm, whereas patients with low inflammatory activity showed a nearly normal secretion pattern. Besides other causes, the influence of mediators of inflammation on hypothalamic centers, analogous to endogenous pyrogen in fever, must be discussed. | |
| 2772543 | [Knee joint replacement with the Motorlet endoprosthesis in patients with rheumatoid arthr | 1989 May | 60 type MOTORLET knee joint endoprostheses are evaluated in this paper. Endoprostheses were implanted in the years 1984-1986 to 51 patients with rheumatoid arthritis and osteoarthrosis of the knee joint. EULAR knee project questionnaire was used to evaluate the results. In 72% of patients the pain completely disappeared both at rest and in movement. The average range of movement, ability to walk and knee joint stability were significantly improved, with highly favourable evaluation in 90% of operated patients. All parameters were compared with the results of 1569 knee joint operations evaluated within the range of EULAR knee project. At the same follow-up period the endoprosthesis type MOTORLET has been comparable to other widely used knee joint replacements. | |
| 3809887 | Serum and synovial fluid histidine: a comparison in rheumatoid arthritis and osteoarthriti | 1986 | The serum and synovial fluid (SF) histidine, sulphydryl, and protein concentrations were compared in simultaneous samples from 84 patients with rheumatoid arthritis (RA) and a control group comprising 29 patients with osteoarthritis (OA). The SF levels of histidine were higher than the serum levels in the RA patients but significantly lower than corresponding results in patients with OA (P less than 0.001). The latter had levels of serum and SF histidine which were equivalent and within the normal range. Greater quantities of protein were found in the SF of the patients with RA compared with the OA group. The serum and SF sulphydryl concentrations expressed as mumol/g protein were low but in equilibrium in patients with RA. However the SF sulphydryl (mumol/g protein) was depressed relative to serum levels in patients with OA. | |
| 2219765 | [Tenoxicam in the long-term treatment of active rheumatoid arthritis]. | 1990 Jun | The authors present the results of six months treatment with Tenoxicam (Tilcotil) in 30 patients with active rheumatoid arthritis. In no instance was it necessary to discontinue treatment, only one female patient complained of transient vertigo. During the final evaluation of the therapeutic effect as regards painfulness, sensitivity on palpation, oedema, restriction of movements, the author did not observe a satisfactory effect only in 8.5-24%. As regards hand grip, 20 m walk and consumption of analgesics the effect was also very satisfactory. Only four patients used occasionally Paracetamol or Alnagon, 1-2 tablets per day. The results achieved with this treatment indicate that it is a very good preparation suited for prolonged therapy of active rheumatoid arthritis, incl. patients of advanced age. Tenoxicam is particularly suited for a single dose per day (20 mg). It can be recommended also combined with gold therapy and treatment with antimalaric drugs. | |
| 3689617 | Bupivacaine with and without adrenaline in interscalene brachial plexus blockade. Studies | 1987 Nov | The action of adrenaline on the pharmacokinetics of bupivacaine has been tested during two successive interscalene brachial plexus blocks in 10 patients with rheumatoid arthritis. The mean venous serum Cmax of bupivacaine after using it with or without adrenaline 1:200000 were 1.49 +/- 0.41 micrograms ml-1 and 2.46 +/- 0.85 micrograms ml-1, respectively. In spite of relatively high total serum concentrations, we could not detect any evidence of toxicity from bupivacaine. Significant tachycardia was seen after bupivacaine with adrenaline, but systolic and diastolic arterial pressures did not change significantly in any session. Marked subjective side effects were noticed only after bupivacaine with adrenaline (shivering twice and palpitations once). The serum protein bound fraction of bupivacaine was higher in rheumatic patients than in our healthy controls: 97.1 +/- 2.4% and 91.3 +/- 3.6%, respectively. Thus bupivacaine as a local anaesthetic agent seems to be even safer in patients with rheumatoid arthritis than in normal healthy volunteers, because of lower free fraction in the former. | |
| 3606681 | Quantitative pain assessment for routine care of rheumatoid arthritis patients, using a pa | 1987 Jun | Pain was assessed quantitatively as a component of routine visits of 385 outpatients with rheumatoid arthritis, using a pain scale based on activities of daily living (ADL) and a visual analog scale. The ADL pain scale met psychometric criteria for validity and reliability. Scores on the 2 pain scales were correlated significantly with one another and with other measures of disease status, including joint count, grip strength, walking time, button test, morning stiffness, erythrocyte sedimentation rate, global self-assessment, ADL difficulty, and ADL dissatisfaction scales. Correlations of ADL pain scale scores with other measures were higher than were correlations of visual analog scale scores with other measures, in both unadjusted and adjusted analyses. Significantly more patients completed the ADL pain scale without assistance than the number of those who completed the visual analog pain scale. The ADL pain scale was more sensitive to problems in ADL than were the ADL scales for difficulty and dissatisfaction. The ADL and visual analog pain scales appear to provide useful data for quantitative assessment of pain in the routine care of rheumatoid arthritis patients. | |
| 3330698 | Genetic analysis in rheumatoid arthritis. | 1986 Jun | The use of heritability studies, haplotype sharing, and lod score analysis are reviewed. Twin and family studies show that any genes conferring susceptibility to rheumatoid arthritis must have a relatively low penetrance. This is a serious obstacle to linkage analysis in families. Where there is a population association, as with DR4, studies of haplotype sharing by affected sibs may yield more information if the observations are compared with the sharing predicted from the population association. | |
| 1930320 | HLA-DPB1*0301 is a major risk factor for rheumatoid factor-negative adult rheumatoid arthr | 1991 Oct | HLA-DPB1 alleles were determined using the polymerase chain reaction and allele-specific oligonucleotide probes in Caucasoid patients with rheumatoid arthritis (RA) and in healthy controls. DPB1*0301 was found to be increased in seronegative patients (50.0% versus 10.8% in controls; relative risk = 8.3, P less than 0.0001). With our previous finding that DPB1*0301 is increased in seronegative children with polyarticular-onset arthritis, the results suggest a relationship between this disease and seronegative RA in adults. | |
| 2672925 | Amiprilose hydrochloride for rheumatoid arthritis. | 1989 Sep 15 | STUDY OBJECTIVE: To assess the safety and efficacy of amiprilose hydrochloride (HCl), a novel synthetic carbohydrate with anti-inflammatory and immunomodulatory properties, in patients with rheumatoid arthritis. DESIGN: Prospective, multicenter, randomized, parallel group, double-blind placebo-controlled 12-week trial. PATIENTS: Two hundred and one functional class I and II patients with definite or classic rheumatoid arthritis, previously untreated with disease modifying antirheumatic drugs. INTERVENTIONS: Patients were withdrawn from nonsteroidal anti-inflammatory drug therapy. Those who flared were randomly assigned to amiprilose HCl, 6 g/d, or placebo for 12 weeks. No concomitant anti-inflammatory or antirheumatic drug therapy was permitted during the study. Combination acetaminophen and propoxyphene napsylate was the only supplemental analgesic medication allowed. MEASUREMENTS AND MAIN RESULTS: The number of painful joints and swollen joints, joint pain and joint swelling indices, left and right grip strength, investigator global assessment, and patient global assessment returned to baseline for the amiprilose group and showed statistically significant (P less than 0.05) differences from the placebo group within 4 to 6 weeks. The protocol criteria for overall therapeutic response were satisfied by 41% of the amiprilose patients, compared with 21% of the placebo group (P = 0.003). Approximately 0.5 tablet per day less analgesic medication was taken by the amiprilose group (P less than 0.05 at weeks 6 and 12). There were no statistically significant differences in morning stiffness, walking time, erythrocyte sedimentation rate, C-reactive protein, or rheumatoid factor between the groups. A similar number of adverse experiences were reported by the patients on amiprilose (67%) and on placebo (63%). One patient on amiprilose developed thrombocytopenia of unknown cause; no other reported adverse effects were serious. CONCLUSIONS: Amiprilose HCl has significant anti-inflammatory activity and a favorable safety profile when used as the sole antirheumatic therapy in patients with active rheumatoid arthritis. Synthetic carbohydrates may represent an important new class of drugs for the treatment of inflammatory, autoimmune diseases. |